ФГБУН ИНСТИТУТ МОЗГА ЧЕЛОВЕКА ИМ. Н.П. БЕХТЕРЕВОЙ РАН

Рассеянный склероз

Рассеянный склероз » Никифорова И.Г. Особенности взаимосвязи нейроиммунологических нарушений и демиелинизирующего поражения при рассеянном склерозе » СПИСОК ЛИТЕРАТУРЫ

СПИСОК ЛИТЕРАТУРЫ

  1. Бисага Г.Н., Грязева И.В., Климович В.В. / Диагностическая информативность определения свободных легких цепей иммуноглобулинов при рассеянном склерозе. // Сборник “Нейроиммунопатология на пороге XXI века». – СПб. – 1993. - С.10-13.
  2. Бисага Г.Н., Поздняков А.В. /Инструментальная диагностика рассеянного склероза. в кн. под ред. Завалишина И.А., Головкина В.И. Рассеянный склероз.// М. – 2000. - С.148-180.
  3. Гусев Е.И., Беляева И.А., Чехонин В.П. и соавт. / Сравнительный клинико-иммунохимический анализ ремиттирующего и вторично-прогрессирующего течения рассеянного склероза. // Ж. Неврологии и психиатрии. – 2000. - №6. – С.51-57.
  4. Гусев Е.И., Бойко А.Н. / Рассеянный склероз: от изучения иммунопатогенеза к новым методам лечения. // М. - изд-во ООО «Губернская медицина». – 2001. – 128с.
  5. Гусев Е.И., Демина Т.Л. / Рассеянный склероз // Consilium Medicum. – Т. 2. - №2. - 2000.
  6. Гусев Е.И., Демина Т.Л., Бойко А.Н. / Рассеянный склероз. // М. – 1997. - 464с.
  7. Демина Т.Л., Гусев Е.И., Бойко А.Н., Пинегин Б.В. / Цитокины в иммунопатогенезе рассеянного склероза. // Ж. Невропатологии и психиатрии. - №5. – 1997. - С.68-73.
  8. Демина Т.Л., Бойко А.Н., Пинегин Б.В., Гусев Е.И. / “Диагностика и лечение демиелинизирующих заболеваний нервной системы”. // Ярославль. - 1998. – С. 26-35.
  9. Жулёв Н.М., Скоромец А.А., Трофимова Т.Н., Тотолян Н.А. / Современная диагностика рассеянного склероза. // СПб: СПбМАПО. – 1998. – 28с.
  10. Калашникова А.А., Калинина Н.М., Бисага Г.Н., Давыдова Н.И. / Особенности субпопуляционного состава лимфоцитов периферической крови больных РС. // «Нейроиммунология» (материалы X Всероссийской коференции). – СПб. – 2001. - С.123.
  11. Крыжановский Г.Н., Магаева С.В., Макаров С.В. / Нейроиммунопатология. // М. - 1997. – 283с.
  12. Марков Д.А., Леонович А.Л. / Рассеянный склероз. // М.: Медицина. - 1976. - 296 с.
  13. Николаева Н.В., Нагелькеркен Л., Петров А.М., Столяров И.Д. / Особенности цитокинового профиля при рассеянном склерозе. // «Нейроиммунология» (материалы X Всероссийской коференции). – СПб. – 2001. С.197-199.
  14. Столяров И.Д. / Взаимодействие нервной и иммунной систем при органических поражениях структур головного мозга. // Дисс… докт. мед. наук. – СПб. - 1996. – 221с.
  15. Столяров И.Д., Головкин В.И., Огурцов Р.П. и др. / Клинико-иммунологический мониторинг больных рассеянным склерозом. // Нейроиммунология. Нейроимидж. (тез. докл. конф.) – СПб. - Лики России. - 1995. – С. 116-118.
  16. Столяров И.Д., Осетров Б.А. / Рассеянный склероз (практическое руководство) // С-Пб.- изд. «ЭЛБИ-СПБ». – 2002. - 175с.
  17. Столяров И.Д., Огурцов Р.П., Петров А.М., Рудас М.С., Вотинцева М.В., Ивашкова Е.В., Бисага Г.Н., Трофимова Т.Н., Бродская З.Л., Скворцова Т.Ю. / Характеристики демиелинизирующего процесса у пациентов с рассеянным склерозом. // Физиология человека. – 1999. - т.25. - №5. - С.31-34.
  18. Тотолян Н.А. / Рассеянный склероз. Диагностика и лечение с позиции доказательной медицины. // Ж. Мир медицины. – 2000. - №5-6. - С. 34-37.
  19. Тотолян Н.А., Лучакова О.В. / Антитела к галактоцереброзидам мозга в сыворотке и цереброспинальной жидкости больных рассеянным склерозом. // Журн. Неврологии и психиатрии – 1996. - №4. – С.75-77.
  20. Фрейдлин И.С. / Иммунная система и ее дефекты. // СПб. - НТФФ “Полисан” – 1998. - 111 с.
  21. Alloza I., Heggarty S., Goris A., Graham C.A., Dubois B., McDonnell G., Hawkins S.A., Carton H., Vandenbroeck K. / Interleukin-12 p40 polymorphism and susceptibility to multiple sclerosis. // Ann Neurol. – 2002. – Vol.52. - №. – P.524-525.
  22. Balashov KE., Smith DR., Khoury SJ., Hafler DA., Weiner HL / Increased interleukin 12 production in progressive multiple sclerosis: induction by activated CD4+ Tcells via CD40 ligand. // Proc Natl Acad Sci USA. – 1997. - Vol. 94. - №2. - P. 599-603.
  23. Balashov KE., Olek MJ., Smith DR., Khoury SJ., Weiner HL. / Seasonal variation of interferon-gamma production in progressive multiple sclerosis. // Ann Neurol. – 1998. – Vol. 44. - №5. – P. 824-828.
  24. Bansil S., Troiano R., Cook CD., Rohowsky-Kochan C. / Serum soluble interleukin-2 receptor levels in chronic progressive, stable and steroid-treated multiple sclerosis. // Acta Neurol Scand. – 1991. – Vol. 84. - №4. – P. 282-285.
  25. Baraczka K., Pozsonyi T., Szongoth M., Nekam K., Megyeri A., balogh Z., Jakab L. / A study of increased levels of soluble vascular cell adhesion molecule-1 (sVCAM-1) in the cerebrospinal fluid of patients with multiple sclerosis and systemic lupus erythematosus. // Acta Neurol Scand. – 1999. - Vol. 99. - №2. – P. 95-99.
  26. Baraczka K., Nekam K., Pozsonyi T., Jakab L., Szongoth M., Sesztak M. / Concentration of soluble adhesion molecules (sVSAM-1, sIcam-1 and sL-selectin) in the cerebrospinal fluid and serum of patients with multiple sclerosis and systemic lupus erythematosus with central nervous involvement. // Neuroimmunomodulation. – 2001. – Vol. 9. - №1. – P. 49-54.
  27. Barkhof F. /Diagnosis and prognosis in MS by magnetic resonance imaging. // J.Multiple sclerosis. - Vol.6. - suppl.1. – 2000. - P. S6-S5.
  28. Barkhof F, Fillipi M, Miller DH, Scheltens P, Campi A, Polman CH, Comi G, Ader HJ, Losseff N, Valk J / Comparison of MRI criteria at first presentation to predict conversion to clinically definite multiple sclerosis. // Brain. – 1997. – Vol. 120. - №11. – P. 2059-2069.
  29. Baumhefener RW., Tourtellotte WW., Syndulko K., et al. / Quantitative multiple sclerosis plaque assessment with magnetic resonance imaging. Its correlation with clinical parameters, evoked potentials, and intra-blood-brain barrier IgG synthesis. // Arch Neurol. – 1990. - № 47. – P. 19-26.
  30. Beatty W.W. / Cognitive andemotionaldisturbances in multiple sclerosis. // Neurol Clin. – 1993. – vol. 11. - № 1. – P. 189-204.
  31. Becher B., Giacomini PS., Pelletier D., McCrea E., Prat A., Antel JP. / Interferon-gamma secretion by peripheral blood T-cell subsets in multiple sclerosis: correlation with disease phase and interferon-beta therapy. // Ann Neurol. – 1999. – Vol. 45. - №2. – P. 247-250.
  32. Bitsch A., Bogumil T., Poser S., Felgenhauer K., Bruck W. / Biological markers for MS. // The International MS Journal. – 1998. - Vol.5. - №1. - P. 7-15.
  33. Bjartmar C, Battistuta J, Terada N, Dupree E, Trapp BD. / N-acetylaspartate is an axon-specific marker of mature white matter in vivo: a biochemical and immunohistochemical study on the rat optic nerve. // Ann Neurol. – 2002. – Vol. 51. - №1. – P. 51-58.
  34. Boiko AN, Kesselring J, Paty D.W. et al / Multiple sclerosis and public health. // Educational and management implications. World Health Organization, Department of Mental Health, Neuroscience and Neurological Disorders. – 1999. - №2. – P. 1-11.
  35. Bodis-Wollner J., Hendley C.D. et al / Visual evoked potentials and the visuorgam in multiple sclerosis. // Ann. Neurol. – 1979. - Vol.5. - N.1. - P.40-47.
  36. Brod SA , Nelson LD., Khan M., Wolinsky JS. / Increased in vitro induced CD4+ and CD8+ T cell IFN-gamma and CD4+ T cell IL-10 production in stable multiple sclerosis. // Int J Neurosci. – 1997. – Vol. 90. - №3-4. – P. 187-202.
  37. Butterworth RJ, Sherwood RA, Bath PM. / Serum S-100 protein in acute stroke. // Stroke. – 1998. – Vol. 29. - №3. – P. 730.
  38. Canella B., Raine CS / The adhesion molecule and cytokine profile of multiple sclerosis lesion. // Ann Neurol. – 1995.- № 37. – P. 424-435.
  39. Carrieri PB, Provitera V., De Rosa T., Tartaglia G., Gorga F., Perrella O. / Profile of cerebrospinal fluid and serum cytokines in patients with relapsing-remitting multiple sclerosis: a correlation with clinical activity. // Immunopharmacol Immunotoxicol. – 1998. – Vol. 20. - №3. – P. 373-382.
  40. Chalon MP., Sindie CJM., Laterre EC / Serum and CSF levels of soluble interleukin-2 receptors in MS and other neurological diseases: a reappraisal. // Acta Neurol Scand. – 1993. - № 87. – P. 77-82.
  41. Correale J, de los Milagros Bassani Molinas M. / Oligoclonal bands and antibody responses in multiple sclerosis. // J Neurol. – 2002. – Vol. 249. - №4. –P. 375-389.
  42. da Costa P., Yasuda CL., Scagliusi SM., Diaz-Bardales BM., Maciel E., Damasceno BP., Blotta MH., Tilbery CP., Santos LM. / Pattern of cytokine secretion by peripheral blood cells of patients with multiple sclerosis in Brazil. // Multiple Sclerosis. – 2000. – Vol. 6. - №5. – P. 293-299.
  43. Davie CA, Barker GJ, Webb SL et al / Persistent functinal deficit in multiple sclerosis and autosomal dominant cerebellar ataxia is associated with axonal loss. // Brain. – 1995. – Vol.118. – P. 1583-1592.
  44. Drulovic J., Mostarica-Stojkovic M., Levic Z., Mesaros S., Stojsavljevic N., Popadic D., Pravica V. / Serum interleukin-12 levels in patients with multiple sclerosis. // Neurosci Lett. – 1998. – Vol. 24. №192. – P. 129-132.
  45. Drulovic J., Mostarica-Stojkovic M., Levic Z., Stojsavljevic N., Pravica V., Mesaros S. / Interleukin-12 and tumor necrosis factor-alpha levels in cerebrospinal fluid of multiple sclerosis patients. // J Neurol Sci. – 1997. – Vol. 147. - №2. – P. 145-150.
  46. Duran I, Martinez-Caceres EM, Rio J, Barbera N, Marzo ME, Montalban X. / Immunological profile of patients with primary progressive multiple sclerosis. Expression of adhesion molecules. // Brain. – 1999. – Vol. 122 ( Pt 12). – P.2297-2307.
  47. Egg R, Reindl M, Deisenhammer F, Linington C, Berger T. / Anti-MOG and anti-MBP antibody subclasses in multiple sclerosis. // Mult Scler. – 2001. - Vol. 7. - №5. – P. 285-289. Evangelou N, Konz D, Esiri MM, Smith S, Palace J, Matthews PM. / Regional Axonal Loss In The Corpus Callosum Correlates With Cerebral White Matter Lesion Volume And Distribution In Multiple Sclerosis. // Brain. – 2000. - Vol. 123. - № 9. – P. 1845-1849.
  48. Fassbender K., Ragoschke A., Rossol S., Schwartz A., Mielke O., Paulig A., Hennerici M. / Increased release of interleukin-12p40 in MS: assotiation with intracerebral inflammation. // Neurology. – 1998. – Vol. 51. - №3. – P. 753-758.
  49. Fazekas F., Offenbacher H., Fuchs S. et al. / Criteria for an increased specificity of MRI interpretation in elderly subjects with suspected multiple sclerosis. // Neurology. - 1988. - Vol.38. – №12. - P. 1822-1825.
  50. Ferribi D, De Seze J, Stojkovic T, Saint Michel t., Gauvrit J.Y, Pruvo JP, Vermersch P. / Cerebral and brainstem atrophy: correlation with disability in multiple sclerosis. // Multiple sclerosis. Clinical and laboratory research. - 2001. - Vol.7. - Suppl.1. - S42. – P. 097.
  51. Fox NC, Jenking C, Leary SM, Stevenson VL, Losseff NA, Crum WR, Harvey RJ, Rosso MN, Thompson AJ, Miller DN / Progreessive cerebral atrophy in multiple sclerosis: a serial study usingregistered, volumetric MRI // J. Neurology. – 2000. – Vol. 54. - №4. – P. 807-812.
  52. Gallo P., Piccinno MG., Tavolato B., Siden AA. / A longitudinal study on IL-2, sIL-2R, IL-4 and IFN-gamma in multiple sclerosis CSF and serum. // J Neurol Sci. – 1991. – Vol. 101. - №2. – P. 227-232.
  53. Giovannoni G., Kieseier B., Hartung HP. / Correlating immunological and magnetic resonance imaging markers of disease activity in multiple sclerosis. // J Neurol Neurosurg Psychiatry. – 1998. – Vol.64. - Suppl 1. – P.S31-6.
  54. Giovannoni G., Miller DN., Losseff NA., Sailer M., Lewellyn-Smith N., Thompson A.J., Thompson EJ. / Serum inflammamtory markers and clinical/MRI markers of disease progression in multiple sclerosis. // J Neurol. - 2001. – Vol. 248. - №6. – P. 487-495.
  55. Giugni E., Pozzilli C., Bastianello S., Gasperini C., Paolillo A., Koudriavtseva T., Frontoni M., Farina D., Bozzao L. / MRI measures and their relations with clinical disability in relapsing-remitting and secondary progressive multiple sclerosis. // Mult Scler. – 1997. – Vol. 3. - №4. – P. 221-225.
  56. Correale J, de Los Milagros Bassani Molinas M. / Oligoclonal bands and antibody responses in Multiple Sclerosis. // J Neurol. – 2002. – Vol. 249. - №34. – P. 375-389.
  57. Gonzalez-Amaro R, Sanchez-Madrid F. / Intercellular adhesion molecules and chemotaxic factors in the pathogenesis of multiple sclerosis. // Rev Neurol. - 2002. – Vol. 35. - №1. - P985-993.
  58. Greenwood J., Etienne-Manneville S., Adamson P., Couraud PO. / Lymphocyte migration into the central nervous system: implication of ICAM-1 signalling at the blood-brain barrier. // Vascul Pharmacol. – 2002. – Vol. 38. - №6. – P. 315-322.
  59. Grimaud J, Barker GJ, Wang L, Lai M, MacManus DG, Webb SL, Thompson AJ, McDonald WI, Tofts PS, Miller DH. / Correlation of magnetic resonance imaging parameters with clinical disability in multiple sclerosis: a preliminary study. // J Neurol. – 1999. – Vol. 246. - №10. – P. 961-967
  60. Grossman R.I., Gonzalez-Scarano F., Atlas S.W., Galetta S., Silberberg D.N. / Multiple sclerosis: gadolinium enchancement in MR imaging. // Radiology. – 1986. – Vol. 161. - №3. – P. 721-725.
  61. Gusev EI., Demina TL., Boiko AN., Pinegin BV. / Prolonged dynamic clinico-immunological observation of 85 patients with definite multiple sclerosis: first steps towards monitoring process activity. // J Neurol. – 1994. – Vol. 241. – P. 500-510.
  62. Gusev E.I., Beliaeva I.A., Chekhonin V.P., Demina T.L., Boiko A.N., Buglak A.V., Gurina O.I. / Clinical and immunochemical characteristics of remittent multiple sclerosis. // Vestn Ross Akad Med Nauk. – 1999. – Vol.7. – P.40-45.
  63. Heesen C., Sieverding F., Buhmann C, Gbadamosi J. / IL-1ra serum levels in disease stages of MS-a marker for progression? // Acta Neurol Scand. – 2000. – Vol. 101. - №20. – P. 95-97.
  64. Hellings N., Gelin G., Medaer R., Bruckers L., Palmers Y., Raus J., Stinissen P. / Longitudinal study of antimyelin T-cell reactivity in relapsing-remitting multiple sclerosis: association with clinical and MRI activity. // J Neuroimmunol. - 2002. – Vol. 126. - №1-2. – P.143-160.
  65. Ho-mig L.S., Siddharthan R., Shermata W.A. et al. / Multiple sclerosis: Correlation of magnetic resonance imaging with cerebrospinal fluid findings. // J. Neurol. Neurosurg. – 1988. - Vol.51. - №2. - P. 277-280.
  66. Huang YM., Xiao BG., Ozenci V., Kouwenhoven M., Teleshova N., Fredrikson S., Link H. / Multiple sclerosis is associated with high levels of circulating dendritic cells secreting pro-inflammatory cytokines. // J Neuroimmunol. – 1999. – Vol. 99. - №1. – P. 82-90.
  67. Huang WX., Huang P., Link H., Hillert J. / Cytokine analysis in multiple sclerosis by competitive RT – PCR: A decreased expression of IL-10 and an increased expression of TNF-alpha in chronic progression. // Multiple Sclerosis. – 1999. – Vol. 5. - №5. – P. 342-348.
  68. Huk W.I., Gademann G., Fridemann G. /Magnetic resonance imaging of central nervous system diseases: Functional anatomy imaging neurological symptoms pathology. // Berlin: Springer Verl. – 1990. - P.450.
  69. Hohlfeld R. / Cytokine networks in MS. // The international MS Journal. - 2000. – Vol. 7. - №2. – P. 50-53.
  70. Kesselring J., Lassmann H. Pathogenesis / Multiple sclerosis. // Ed. J. Kesselring.- Cambridge University Press. – 1997. - P.54-62.
  71. Khoury SJ., Guttmann CR., Orav EJ., Kikinis R., Jolesz FA., Weiner HL. / Changes in activated T cells in the blood correlate with disease activity in multiple sclerosis. // Arch Neurol. – 2000. – vol. 57. - №8. – P. 1183-1189.
  72. Khoury SJ., Orav EJ., Guttmann CR., Kikinis R., Jolesz FA., Weiner HL. / Changes in serum levels of ICAM and TNF-R correlate with disease activity in multiple sclerosis. // Neurology. – 1999. – Vol. 53. - №4. – P. 758-764.
  73. Killestein J., Rep MHG., Barkhof F., Roos MTL., Ader HJ., Van Lier RAW., Polman CH. / Active MRI lesion appearance in multiple sclerosis patients is assotiated with a decreased in circulating interferon- and interleukin-4 producing T-cells. // Revue Neurologique. – 2000. – T.156. - Suppl.3. – P. 77-78.
  74. Killestein J., Rep MN, Barkhof F., Roos MT, Ader HJ, van Lier RA, Polman CH. / Active MRI lesion appearence in MS patients is preceded by fluctuations in circulating T-helper 1 and 2 cells. // J. Neuroimmunology. – 2001. – Vol. 118. - №2. – P. 286-294.
  75. Kittur SD., Kittur DS., Soncrant TT., Rapoport SI, Tourtellotte WW, Nagel JE, Adler WH. / Soluble interleukin-2 receptors in cerebrospinal fluid from individuals with various neurological disorders. // Ann Neurol. – 1990. - Vol. 28. - P.168-173.
  76. Kivisakk P., Stawiarz P., matusevicius D., Fredrikson S., Soderstrom M., Hindmarsh T., Link H. / High numbers of perforin mRNA expressing CSF cells in multiple sclerosis patients with gadolinium-enhancing brain MRI lesions. // Acta Neurol Scand. – 1999. – Vol. 100. - №1. – P. 18-24.
  77. Koudriavtseva T, Thompson AJ, Fiorelli M, Gasperini C, Bastianello S, Bozzao A, Paolillo A, Pisani A, Galgani S, Pozzilli C / Gadolinium enchanced MRI predicts clinical and MRI disease activity in relapsing-remitting multiple sclerosis. // J. Neurol Neurosurg Psychiatry. – 1997. – Vol. 62. - №3. – P. 285-287.
  78. Krakauer M, Schaldemose Nielsen H, Jensen J, Sellebjerg F. / Intrathecal synthesis of free immunoglobulin light chains in multiple sclerosis. // Acta Neurol Scand. – 1998. – Vol. 98. - №3. – P.161-165.
  79. Kraus J, Engelhardt B, Chatzimanolis N, Bauer R, Tofighi J, Kuehne BS, Laske C, Stolz E, Frielinghaus P, Schaefer C, Blaes F, Traupe H, Kaps M, Oschmann P. / Cell surface bound and soluble adhesion molecules in CSF and blood in multiple sclerosis: correlation with MRI-measures of subclinical disease severity and activity. // J Neuroimmunol. – 2002. – Vol. 122. - №1-2. – P. 175-185.
  80. Kraus J., Oschmann P., Engelhardt B., Kuehne BS., Tofighi J., Chatzimanolis N., Bauer R., Diehl H., Laske C., Stolz E., Schaefer C., Traupe H., Kaps M. / Correlation of adgesion molecules in blood with disease burden in multiple sclerosis assessed by cranial MRI imaging. // Revue Neurologique. – 2000. – T.156. - Suppl.3. – P.78.
  81. Kurtzke J.F. / Rating neurologic impairment in multiple sclerosis: an expanded disability status scale (EDSS). // Neurology. – 1983. – Vol. 33. - №12. – P. 1444-1452.
  82. Lamers KJ., de Reus HP., Jongen PJ. / Myelin basic protein in CSF as indicator of disease activity in multiple sclerosis. // Mult Scler. – 1998. – Vol. 4. - №3. – P. 124-126.
  83. Li D.K., Zhao G., Paty D.W. / T2 hyperintensities: findings and significans. // Neuroimaging Clin N Am. – 2000. – Vol. 10. - №4. – P. 717-738.
  84. Link H., Duran I., Jardi R, Tintore Subirana M.D., Falip Centellas M. / Clinical usefulness of oligoclonal bands. // RevNeurol. – 2001. – Vol. 32. - №12. – P. 1120-1124.
  85. Losseff N.A., Wang L., Lai H.M., et al. / Progreessive cerebral atrophy in multiple sclerosis: a serial MRI study. // Brain. – 1996. – Vol.119. – P.2009-2019.
  86. Losy J., Niezgoda A. / Il-18 in patients with multiple sclerosis. // Acta Neurol Scand. – 2001. – Vol. 104. - №3. – P.171-173.
  87. Maimone D., Gregory S., Arnason B.G., Reder A.T. / Cytokine levels in the cerebrospinal fluid and serum of patients with multiple sclerosis. // J Neuroimmunol. – 1991. – Vol. 32. - №1. – P.67-74.
  88. Magdic B., Ilic T., Cirkovic S., Mijuskovic A. / Magnetic resonance findings and cerebrospinal fluid parameters in the evaluation of blood-brain barrier status and multiple sclerosis activity. // Vojnosanit Pregl. – 1998. – Vol. 55. - №5. – P. 483-488.
  89. Makhlouf K., Weiner HI., Khoury SJ. / Increased percentage of IL-12+ monocytes in the blood correlates with the presence of active MRI lesion in MS. // J Neuroimmunol. – 2001. – Vol. 119. - №1. – P. 145-149.
  90. Mammi S., Filippi M., martinelli V., Campi A., Colombo B., Scotti G., Canal N., Comi G. / Correlation between brain MRI lesion volume and disability in patients with multiple sclerosis. // Acta Neurol Scand. – 1996. – Vol. –№2. – P. 93-96.
  91. Manova M.G., Kostadinova I.I., Chalakova-Atanasova N.T., Temenlieva V.K., Petrova N.S. / Clinico-electrophysiological correlates in patients with relapsing-remitting multiple sclerosis. // Folia Med (Plovdiv). – 2001. - Vol. 43. - №3. – P. 5-9.
  92. Matthews W.B. / McAlpine's multiple sclerosis (Second edition). // Churchill Livingstone, Edinburgh 1991.
  93. McDonald W., Compston A., Edan G., Goodkin D., Hartung H., Lublin FD., McFarland HF., Paty DW., Polman CL., Reingold SC., Sandberg-Wollheim M., Sibley W., Thompson A., Noort S., Weinshenker BY., Wolinsky JS. /Recommended Diagnostic Criteria for Multiple sclerosis: Guidelines from the International Panel on the Diagnosis of Multiple Sclerosis. // Ann Neurol. – 2001. – Vol. 50. - №1. – P. 121-127.
  94. McDonnell G.V., McMillan S.A., Douglas J.P., Droogan A.G., Hawkins S.A. / Raised CSF levels of soluble adhesion molecules across the clinical spectrum of multiple sclerosis. // J Neuroimmunol. – 1998. – Vol. 85. - №2. – P. 186-192.
  95. McDonnel G.V., McMillan S.A., Douglas J.P., Droogan A.G., Hawkins S.A. / Serum soluble adhesion molecules in multiple sclerosis: raised sVCAM-1, sISAM-1 and sE-selectin in primary progressive disease. // J Neurol. – 1999. - Vol. 246. - №2. – P. 87-92.
  96. Miki Y., Grossman RI., Udupa JK., Wei L., Polansky M., Mannon LJ., Kolson DL. / Relapsing-remitting multiple sclerosis: longitudinal analysis of MR imaging—lack of correlation between changes in T2 lesion volume and clinical findings. // Radiology. – 1999. – Vol. 213. - №2. – P. 395-399.
  97. Miller D.H., Grossman R.I., Reingold S.C., McFarland H.F. / The role of magnetic resonance technigues in understanding and managing multiple sclerosis. // Brain. – 1998. – Vol. 121. – P. 3-24.
  98. Miller D.H., Khan O.A., Sheremata W.A., Blumhardt L.D., Rice G.P., Libonati M.A., Willmer-Hulme A.J., Dalton C.M., Miszkiel K.A., O'Connor P.W. / A controlled trial of natalizumab for relapsing multiple sclerosis. // N Engl J Med. – 2003. - Vol. 348. - №1. – P.15-23.
  99. Missler U., Wandinger K.P., Wiesmann M., Kaps M., Wessel K. / Acute exacerbation of multiple sclerosis increases plasma levels of S-100 protein. // Acta Neurol Scand. – 1997. – Vol. 96. - №3. – P. 142-144.
  100. Mix E., Olsson T., Correale J., Kostulas V., Link H. / CD4+, CD8+, and CD4- CD8- T cells in CSF and blood of patients with multiple sclerosis and tension headache. // Scand J Immunol. – 1990. – Vol. 31. - №4. – P. 493-501.
  101. Mokhtarian F., Shi Y., Shirazian D., Morgante L., Miller A., Grob D. / Defective production of anti-inflammatory cytokine, TGF-beta by T cell lines of patients with active multiple sclerosis. // J Immunol. – 1994. – Vol. 152. -№12. – P. 6003-6010.
  102. Monteyne P., van Antwerpen MP., Sindic CJ. / Expression of costimulatory molecules and cytokines in CSF and peripheral blood mononuclear cells from multiple sclerosis patients. // Acta Neurol Belg. – 1999. – Vol. 99. - №1. – P. 11-20.
  103. Mossner S., Fassbender K., Kuhnen K. et al / Vascular cell adhesion moleculae – a new approach to detect endotelial cell activation in MS and encephalitis in vitro. // Acta Neurol Scand.. – 1996. – Vol. 93. – P. 118-122.
  104. Navikas V., Link H. / Review: cytokines and the pathogenesis of multiple sclerosis. // J Neurosci Res. – 1996. – Vol. 45. - №4. – P. 322-333.
  105. Nicoletti F., Patti F., DiMarco R. et al / Circulation serum levels of IL-1ra in patients with relapsing-remitting multiple sclerosis are normal during remission phases but significancy increased either during exacerbation’s or in response to IFN-beta treatment. // Cytokine. – 1996. – Vol. 8. – P. 395-4000.
  106. Nicoletti F., Patti F., Coeuzza C. et al. / Elevated serum levels of IL-12 in chronic progressive multiple sclerosis. // J. Neuroimmunology. – 1996. - Vol.70.. - P.87-90.
  107. Odinak M.M., Bisaga G.N., Kalinina N.M., Akimov S.B., Davydova N.I. / Immunogenetic cytokine restriction in multiple sclerosis. // Zh Nevrol Psikhiatr Im SS Korsakova. – 2001. – Vol. 101. - №9. – P. 39-44.
  108. Oger J., Kastrukoff L., O'Gorman M., Paty D.W. / Progressive multiple sclerosis: abnormal immune functions in vitro and aberrant correlation with enumeration of lymphocyte subpopulations. // J.Neuroimmunol. -1986 - Vol.12 - P.37.
  109. Oreja-Guevara C., Sindern E., Raulf-heimsoth M., Malin JP. / Analysis of lymphocyte subpopulations in cerbrospinal fluid and peripheral blood in patients with multiple sclerosis and inflammatory disease of the nervous system. // Acta Neurol Scand. – 1998. - vol. 98. - №5. – P. 310-313.
  110. O'Riordan J.I., Thompson A.J., Kingsley D.P., MacManus D.G., Kendall B.E., Rudge P., McDonald W.I., Miller D.H. / The prognostic value of brain MRI in clinically isolated syndromes of the CNS. A 10-year follow-up. // Brain. – 1998. – Vol. 121. - №3. – P.495-503.
  111. Ozenci V., Kouwenhoven M., Huang Y.M., Kivisakk P., Link H. / Multiple sclerosis is associated with an imbalance between tumor necrosis factor-alpha (TNF-alpha) and IL-10-secreting blood cells that is corrected by interferon-beta (IFN-beta) treatment. // Clin Exp Immunol. – 2000. – Vol. 120. - №1. – P. 147-153.
  112. Paty D.W., Oger J.F., Kastrikof L.F. / MRI in the diagnosis of MS: a prospektive study with comparison of clinical evaluation, evokepotentials, oligoclonal banding and CT. // Neurology. – 1988. – Vol. 38. – №.2. – P. 180-184.
  113. Petereit H.F., Pukrop R., Fazekas F., Bamborschke S.U., Ropele S., Kolmel H.W., Merkelbach S., Japp G., Jongen P.J., Hartung H.P., Hommes O.R. / Low interleukin-10 production is associated with higher disability and MRI lesion load in secondary progressive multiple sclerosis. // J Neurol Sci. – 2003. – Vol. 206. – №2. – P.209-214.
  114. Petrov A., Nikolaeva N., Ivashkova E., Ilves A., Seliverstova N., Stoliarov I. / Cytokine profile and neuropsychological battery in multiple sclerosis patients. variations with disease stage. // Revue Neurologique. – 2000. – T.156. - Suppl.3. – P. 175-176.
  115. Poser C.M. et al / New diagnostic criteria for multiple sclerosis: guidelines for research protocols. // Ann Neurol. – 1983. - Vol.13. – P. 227-231.
  116. Prat P., Pelletier D., Duquette P., Arnold D.L., Antel J.P. / Heterogeneity of T-lymphocyte function in primary progressive multiple sclerosis: relation to magnetic resonance imaging lesion volume. // Ann Neurol. – 2000. – Vol. 47. - №2. – P. 234-237.
  117. Rand K.H., Houk H., Denslow N.D., Heilman K.M. / Molecular approach to find target(s) for oligoclonal bands in multiple sclerosis. // J. Neurol Neurosurg Psychiatry. – 1998. – Vol. 65. - №1. – P. 48-55.
  118. Rieckman P., Albrecht M., Kitze B., et al / Cytokine mRNA levels in mononuclearblood cells from patients with multiple sclerosis. // Neurology. - 1994. – Vol.44ю. – P. 1523-1526.
  119. Riekmann P., Altenhofen B, Riegel A., Kallmann B., Felgenhauer K. / Correlation of soluble adhesion molecules in blood and cerebrospinal fluid with magnetic resonance imaging activity in patients with multiple sclerosis. // Mult. Scler. – 1998. – Vol. 4. - №3. – P. 178-182.
  120. Rohowsky-Kochan C., Molinaro D., Cook CD. / Cytokine secretion profile of mielin basic protein-specofic T cells in multiple sclerosis. // Mult Scler. - 2000. – Vol. 6. - №2. – P. 69-77.
  121. Rovaris M., Filippi M. / Contrast enhancement and the acute lesion in multiple sclerosis. // Neuroimaging Clin N Am. – 2000. – Vol. 10. - №4. – P. 705-716.
  122. Rovaris M., Rocca M.A., Capra R., Prandini F., Martinelli V., Comi G., Filippi M. / A comparison between the sensitivities of 3-mm and 5-mm thick serial brain MRI for detecting lesion volume changes in patients with multiple sclerosis. // J Neuroimaging. – 1998. – Vol. 8. - №3. – P. 144-147.
  123. Rovaris M., Codella M., Moiola L., Ghezzi A., Zaffaroni M., Mancardi G., Capello E., Sardanelli F., Comi G., Filippi M. / Effect of glatiramer acetate on MS lesions enhancing at different gadolinium doses. // Neurology. – 2002. - Vol. 59. - №9. – P. 1429-1432.
  124. Rubeza G., Podack ER., Sepcic J., Rukavina D. / Increased perforin expression in multiple sclerosis patients during exacerbation of disease in peripheral blood lymphocytes. // J Neuroimmunol. – 1997. – Vol. 74. - №1-2. – P. 198-204.
  125. Rudick R.A., Goodkin D.E. / Multiple sclerosis Therapeutics. // 2-nd ed. – London: M.Dunitz. - 2000. –573p.
  126. Sailer M, Losseff NA, Wang L, Gawne-Cain ML, Thompson AJ, Miller DN / T1 lesion load and cerebral atrophy as a marker for clinical progression in patients with multiple sclerosis. A progressive 18 months follow-up study // Eur J. Neurol. – 2001. – Vol. 8. - №1. – P. 37-42.
  127. Sharief M.K., Noory M.A., Ciardi M., Cirelli A., Thompson E.J. / Increased levels of circulating ICAM-1 in serum and cerebrospinal fluid of patients with active multiple sclerosis. Correlation with TNF-alpha and blood-brain barrier damage. // J. Neuroimmunol. – 1993. – Vol. 43. – №1-2. - P. 15-21.
  128. Shaw C.E., Dunbar P.R., Macaulay H.A., Neal T.J. / Measurement of immune markers in the serum and cerebrospinal fluid of multiple sclerosis patients during clinical remission. // J. Neuroimmunol. – 1995. – Vol. 242. - №2. - P. 53-58.
  129. Sobel R.A., Mitchel M.E., Fondren G. / Intercellular adhesion molecule-1 (ICAM-1) in cellular immune reactions in the human central nervous system. // Am J Pathol. – 1990. – Vol. 136. – №6. – P. 1309-1316.
  130. Spuler S., Yousry T., Scheller A., Voltz R., Holler E., Hartmann M., Wick M., Holfeld R. / Multiple sclerosis: prospective analysis of TNF-alpha and 55kDa TNF receptor in CSF and serum in correlation with clinical and MRI activity. // J Neuroimmunol. – 1996. – Vol. 66. - №1-2. – P. 57-59.
  131. Stawiarz L., Helms G., Link H. / Changes in tissue water content in MS lesion at different stages of their evolution evaluated by proton MRS. // Multiple sclerosis: clinical and laboratory research. – 1997. – Vol.3. – P.295.
  132. Stouras P. / The serum levels of interleukin-1 in primary and secondary chronic progressive course of multiple sclerosis. // Rev Neurol (Paris). – 2000. - Suppl.3 . - P.92.
  133. Tilg H., Kaser A. / Interferons and their role in inflammation. // Curr Pharm Des. – 1999. – Vol. 5. – P. 771-785.
  134. Totolian N.A., Griazeva I.V., Klimovich V.B., Totolian A.A. / Free light-chain immunoglobulins in the biological fluids of patients with multiple sclerosis. // Zh Nevropatol Psikhiatr Im SS Korsakova. – 1997. – Vol. 97. - №5. – P. 34-38.
  135. Tsukuda N., Matsuda M., Miyagi K., Yanagisawa N. / In vitro intercellular adhesion moleculae 1 expression on brain endothelial cells in multiple sclerosis. // J Neuroimmunol. – 1994. – Vol. 49. –P. 181-187.
  136. Valli A., Sette A., Kappos L., Oseroff C., Sidney J., Miescher G., Hochberger M., Albert E.D., Adorini L. / Binding of myelin basic protein peptides to human histocompatibility leukocyte antigen class II molecules and their recognition by T cells from multiple sclerosis patients. // J Clin Invest. – 1993. – Vol. 91. -№2. – P. 616-628.
  137. van Boxel-Dezaire AHH., Hoff SCJ., van Oosten B.W.et al / Decreased intrleukin-10 and increased interleukin-12p40 mRNA are associated with desease activity and characterize different stages in multiple sclerosis. // Ann Neurol. – 1999. – Vol. 45. – P. 695-703.
  138. Wang HY, Matsui M, Saida T. / Immunological disturbances in the central nervous system linked to MRI findings in multiple sclerosis. // J Neuroimmunol. – 2002. – Vol. 125. - № 1-2. – P. 149-154.
  139. Weiner HL., Guttmann CR., Khoury SJ., Orav EJ., Hohol MJ., Kikinis R., Jolesz FA. / Serial magnetic resonance imaging in multiple sclerosis: correlation with attacks, disability, and disease stage. // J Neuroimmunol. - 2000. – Vol. 104. - №2. – P.164-173.
  140. Weiner H., Khoury S.J. / Cytokine regulation in multiple sclerosis. // Multiple Sclerosis. – 2002. – Vol. 8. - №1. – P. S14.
  141. Wilson M, Morgan PS, Lin X, Turner BP, Blumhardt LD / Qunitative diffusion weighted magnetic resonance imaging, cerebral atrophy, and disability in multiple sclerosis. // J. Neurol. Neurosurg. Psychiatry. – 2001. - Vol. 70. - №3. - P. 318-22.
  142. Woodroofe MN., Cuzner ML. / Cytokine mRNA expression in inflammatory multiple sclerosis lesions: detection by non-radioactive in situ hybridization. // Cytokine. – 1993. – Vol. 5. - №6. – P. 583-588.
  143. Wucherpfenning K.W., Weiner H.L., Hafler D.A. / T-cell recognition of myelin basic protein. // Cell. – 1995. – Vol.80 – P.695-705.
  144. Young I.R., Hall A.S., Pallis C.A. et al. /Nuclear magnetic resonance imaging of the brain in multiple sclerosis // Lancet. – 1981. - Vol. 2. - P.1063`-1066
Уважаемые пользователи!
Наши специалисты готовы ответить на Ваши вопросы в разделе «Форум».

© rscleros.ru 2009-2017